Ava bags $10M for wrist-worn fertility tracker

Ava fertility bracelet. Image: Ava

Ava, which focuses on women’s reproductive health, reeled in a $9.7 million Series A funding round, which will drive product development and scale production of its fertility-tracking wristband, as well as propel its expansion into European markets.

The Zurich-based company launched the Ava fertility bracelet in the U.S. in July. It is the first device to track the fertile days of a woman’s menstrual cycle in real time, according to the company.

Worn at night, the device continuously records data on nine physiological measures that reflect a rise in hormones associated with ovulation, according to a statement from the company. These measures include pulse, breathing rate, sleep quality and temperature. In the morning, the data is synced with a mobile app. A recent study showed the tracker was able to identify an average of 5.3 fertile days per cycle with 89 percent accuracy.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"We are excited to see the response from investors, and even more importantly, from the thousands of women from all over the world to our Ava bracelet,” said CEO Pascal Koenig, in the statement. “Certainly the need for a better solution to helping couples conceive is real. With these funds, we'll be able to further accelerate our traction, and continue on our mission of developing technology that improves the reproductive health of women worldwide."

Polytech Ecosystem Ventures led the financing, with participation from new investors Blue Ocean Ventures and Global Sources, as well as from existing backers Swisscom and ZKB.

Ava will use the funding to develop the product further as well as to scale production of the fertility tracker to meet consumer demand, said Lea von Bidder, Ava Science president and vice president of marketing, in the statement. It will also ramp up the company’s research efforts—the bracelet is currently in a second clinical study—and bankroll its expansion into some European countries next year.


Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.